Dewpoint Overview
- Founded
- 2018
- Status
- Private
- Employees
- 120
- Latest Deal Type
- Series C
- Latest Deal Amount
- $150M
- Investors
- 16
Dewpoint General Information
Description
Developer of a healthcare technology designed to identify novel drugs across a wide spectrum of diseases. The company's technology use machine-learning-based image analysis tools for visualizing condensates and offers an engine for genetically linked condensatopathy, a collection of engineered cell lines with trackable condensates to prevent harmful protein sequestration, enabling healthcare providers to have access to new therapies to address unmet needs.
Contact Information
Website
www.dewpointx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 451 D Street
- Suite 104
- Boston, MA 02210
- United States
+1 (617) 000-0000
Dewpoint Timeline
Dewpoint Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 03-Feb-2022 | $150M | 00000 | 00000 | Completed | Generating Revenue |
| 2. Early Stage VC (Series B) | 29-Sep-2020 | 0000 | 00000 | 00000 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A) | 30-Jan-2019 | $59.2M | $59.2M | 000.00 | Completed | Startup |
Dewpoint Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 000 | |
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series A1 | 4,166,666 | $0.000100 | $1.2 | $1.2 | 1x | $1.2 | 1.99% | |
| Series A | 63,283,217 | $0.000100 | $1 | $1 | 1x | $1 | 30.27% |
Dewpoint Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a healthcare technology designed to identify novel drugs across a wide spectrum of diseases. The company's
Drug Discovery
Boston, MA
120
As of 2022
00000
0000
0000-00-00
00000000000
00000
0000000
cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culp
0000 000000000
Cambridge, MA
000
As of 0000
00000
00000000000
00000
0000000
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariat
0000 000000000
Singapore, Singapore
00
As of 0000
00000
00000 00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialDewpoint Competitors (49)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
| 0000000 | Venture Capital-Backed | Singapore, Singapore | 00 | 00000 | 00000 00000 | |
| 000 00000000000000 | Venture Capital-Backed | Philadelphia, PA | 00 | 000.00 | 00000000000 | 000.00 |
| 00000000 000000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
| 0000000 | Venture Capital-Backed | Framingham, MA | 00 | 000.00 | 00000000000 | 000.00 |
Dewpoint Patents
Dewpoint Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210208153-A1 | Methods of screening for condensate-associated specificity and uses thereof | Pending | 18-Sep-2019 | 000000000 | |
| AU-2020219368-A1 | Methods of characterizing condensate-associated characteristics of compounds and uses thereof | Pending | 08-Feb-2019 | 0000000000 | |
| CA-3127237-A1 | Methods of characterizing condensate-associated characteristics of compounds and uses thereof | Pending | 08-Feb-2019 | 0000000000 | |
| US-20200284801-A1 | Methods of characterizing condensate-associated characteristics of compounds and uses thereof | Pending | 08-Feb-2019 | 000000000 | |
| US-20180137338-A1 | System and method for classifying and segmenting microscopy images with deep multiple instance learning | Granted | 16-Nov-2016 | G06K9/00147 | 00 |
Dewpoint Executive Team (9)
Dewpoint Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ameet Nathwani MD | Self | Chief Executive Officer & Board Member | 000 0000 |
| Amir Nashat Ph.D | Self | Chairman | 000 0000 |
| Amy Schulman JD | Self | Board Member | 000 0000 |
| Anthony Hyman Ph.D | Dewpoint | Co-Founder & Board Member | 000 0000 |
| Giuseppe Ciaramella Ph.D | Self | Board Member | 000 0000 |
Dewpoint Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialDewpoint Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 3E Bioventures Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| General Catalyst | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Mirae Asset Capital | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Mubadala Capital-Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| NS Investment | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |